StemCell Therapy

A rating of 95 puts Cytokinetics, Inc. (CYTK) near the top of the Biotechnology industry according to InvestorsObserver. Cytokinetics, Inc.'s score of 95 means it scores higher than 95% of stocks in the industry. Cytokinetics, Inc. also received an overall rating of 77, putting it above 77% of all stocks. Biotechnology is ranked 26 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 77 means the stock is more attractive than 77 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Cytokinetics, Inc. (CYTK) stock is trading at $24.50 as of 2:24 PM on Friday, Aug 28, a gain of $0.86, or 3.64% from the previous closing price of $23.64. The stock has traded between $23.65 and $24.95 so far today. Volume today is 824,667 compared to average volume of 1,027,773.

To see the top 5 stocks in Biotechnology click here.

Visit link:
Is Cytokinetics, Inc. (CYTK) the Top Pick in the Biotechnology Industry? - InvestorsObserver

This entry was posted on August 28, 2020 at 11:55 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |